{"id":"NCT02281357","sponsor":"AstraZeneca","briefTitle":"Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma","officialTitle":"A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolescents With Oral Corticosteroid Dependent Asthma (TROPOS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-19","primaryCompletion":"2017-09-07","completion":"2017-09-07","firstPosted":"2014-11-03","resultsPosted":"2018-05-16","lastUpdate":"2019-03-15"},"enrollment":140,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Tralokinumab","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tralokinumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid dependent Asthma.","primaryOutcome":{"measure":"Percent Change From Baseline in the Final Daily, Average, OCS Dose at Week 40 While Not Losing Asthma Control.","timeFrame":"Baseline (Week 0) and Week 40","effectByArm":[{"arm":"Tralokinumab","deltaMin":-37.62,"sd":4.98},{"arm":"Placebo","deltaMin":-29.85,"sd":4.98}],"pValues":[{"comp":"OG000 vs OG001","p":"0.271"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":51,"countries":["United States","Belgium","France","Germany","Netherlands","Poland","Ukraine"]},"refs":{"pmids":["30442714","29536781"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2966&filename=d2210c00013-revised-csp-4_Redacted_PDFA.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2966&filename=d2210c00013-sap-ed-3_redaction_proposed_Redacted_PDFA.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":70},"commonTop":["Viral upper respiratory tract infection","Bronchitis","Headache","Asthma","Sinusitis"]}}